AA
OLMA icon

ALPS Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

ALPS Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
88,649
+24,614
+38% +$330K 0.01% 674
2026
Q1 		$955K Sell
64,035
-557
-0.9% -$12.4K ﹤0.01% 591
2025
Q4 		$1.61M Buy
64,592
+32,082
+99% +$571K 0.01% 432
2025
Q3 		$318K Sell
32,510
-4,400
-12% -$26.4K ﹤0.01% 949
2025
Q2 		$157K Sell
36,910
-13,574
-27% -$60.5K ﹤0.01% 1016
2025
Q1 		$190K Buy
50,484
+4,149
+9% +$20.9K ﹤0.01% 964
2024
Q4 		$270K Buy
46,335
+644
+1% +$6.43K ﹤0.01% 949
2024
Q3 		$546K Buy
45,691
+2,039
+5% +$26.1K ﹤0.01% 594
2024
Q2 		$472K Buy
43,652
+4,791
+12% +$52K ﹤0.01% 589
2024
Q1 		$440K Buy
38,861
+698
+2% +$9.01K ﹤0.01% 611
2023
Q4 		$535K Buy
+38,163
New +$513K ﹤0.01% 594

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

ALPS Advisors's OLMA Position: Q2 2026 in Review

ALPS Advisors increased its Olema Pharmaceuticals (OLMA) stake by 38% in Q2 2026, buying an estimated $330K and bringing the position to 88,649 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #674.

ALPS Advisors first reported a position in OLMA in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.61M in Q4 2025. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • ALPS Advisors held 88,649 shares of Olema Pharmaceuticals worth $1.11M as of Q2 2026.
  • ALPS Advisors bought 24,614 Olema Pharmaceuticals shares in Q2 2026, an estimated $330K.
  • Olema Pharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #674 holding.
  • ALPS Advisors first reported a position in Olema Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • ALPS Advisors's Olema Pharmaceuticals position peaked at $1.61M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.